|Bid||106.45 x 800|
|Ask||106.87 x 1000|
|Day's Range||105.72 - 107.10|
|52 Week Range||82.59 - 108.95|
|Beta (5Y Monthly)||0.84|
|PE Ratio (TTM)||20.09|
|Forward Dividend & Yield||2.12 (1.98%)|
|Ex-Dividend Date||Jan 11, 2020|
|1y Target Est||N/A|
Today we'll look at Quest Diagnostics Incorporated (NYSE:DGX) and reflect on its potential as an investment. To be...
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
In 2012 Steve Rusckowski was appointed CEO of Quest Diagnostics Incorporated (NYSE:DGX). This analysis aims first to...
Moody's Investors Service ("Moody's") assigned a Baa2 rating to the proposed offering of senior unsecured notes of Quest Diagnostics Incorporated ("Quest"). There are no changes to Moody's existing ratings of Quest including the Baa2 senior unsecured long-term rating. Further, Quest has a long track record of maintaining modest financial leverage and generating stable cash flows, which Moody's expects will continue.
"The global economic environment is very favorable for investors. Economies are generally strong, but not too strong. Employment levels are among the strongest for many decades. Interest rates are paused at very low levels, and the risk of significant increases in the medium term seems low. Financing for transactions is freely available to good borrowers, […]
Today I will take a look at Quest Diagnostics Incorporated's (NYSE:DGX) most recent earnings update (30 September...
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Does the November share price for Quest Diagnostics Incorporated (NYSE:DGX) reflect what it's really worth? Today, we...
Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The last 12 months is one of those periods, as the Russell 2000 […]
Moody's rating action reflects a base expected loss of 16.5% of the current pooled balance, compared to 11.3% at Moody's last review. Exceptions to this approach exist for the following disclosures, if applicable to jurisdiction: Ancillary Services, Disclosure to rated entity, Disclosure from rated entity.
Quest Diagnostics (DGX) is likely to have retained its two-pronged agenda to accelerate growth and drive operational excellence in the third quarter.
The long-anticipated offices were first approved in 2015, and had been under construction for the last two years.
This is the second of two stories that Investopedia is devoting to a report from Goldman Sachs recommending stocks with longterm stable profit growth.
Managenment believes that under Schechter's term with Paul and John's crucial support, LabCorp (LH) looks well-positioned to grow and thrive in times ahead.
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Quest...